Allogene Therapeutics, Inc. (ALLO)
$1.30+0.78%Close
SELLCRISIS · day 27
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $449M
- Beta
- 0.48
- P/E (TTM)
- -1.94
- Short % float
- 21.37%
- Days to cover
- 9.0
- SI change
- -6.7%
- 1W
- -9.09%
- 1M
- -24.42%
- vs SPY 1W
- -8.95%
- vs SPY 1M
- -26.92%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 0
- VALUE
- 7
- GROWTH
- 17
- GARP
- 5
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-30.0%
REV YoY-
ROE-50.0%
EPS YoY-
ROA-30.1%
GROSS100
OP-3886
NET-3567
[VALUATION]
P/E TTM-1.94
P/E FWD-
SECTOR PE20.48
INDUSTRY PE13.99
P/B0.98
P/FCF-
EV/EBITDA-3.15
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E16.13
ALTMAN Z-
CURR RATIO10.72
ND/EBITDA-
BETA0.48
Company news
FAQ
- What is LOPJLB’s current signal on ALLO?
- LOPJLB’s latest quantitative signal on Allogene Therapeutics, Inc. (ALLO) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is ALLO in?
- Allogene Therapeutics, Inc. (ALLO) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Allogene Therapeutics, Inc. (ALLO) do?
- Allogene Therapeutics, Inc. operates as a clinical-stage immuno-oncology firm dedicated to the creation and commercialization of genetically engineered allogeneic T-cell therapies for the treatment of various cancers. A pivotal product in their development pipeline is UCART19, an allogeneic chimeric antigen receptor (CAR) T-cell therapy. This candidate is being developed, manufactured, and prep…